Senores Pharmaceuticals Limited is coming up with an IPO consisting of a fresh issue of 1.28 crore shares worth INR 500 crores and an offer to sell 0.21 crore existing shares worth INR 82.11 crores. The company aims to fund subsidiaries, repay borrowings, support working capital, and pursue strategic growth. 

Senores Pharmaceuticals IPO – Important Dates 

Senores Pharmaceuticals Limited IPO – Company Profile 

Senores Pharmaceuticals Limited is a global research-driven company developing and manufacturing speciality, complex pharmaceutical products for regulated markets like the US, Canada, and the UK. It leverages R&D expertise, strategic partnerships, and market-driven approaches. 

The company’s Regulated Markets Business, via subsidiaries Havix and SPI, drives growth by offering ANDA products, sourced products, and CDMO/CMO services. It primarily targets the US, Canada, and the UK while expanding into newly regulated markets. 

Leveraging insights from US and Canadian markets, the company introduced complex patented molecules like Apixaban and Sacubitril+Valsartan in Emerging Markets and received approvals to market these innovative products across various therapeutic areas. 

Senores Pharmaceuticals Ltd IPO Fundamental Analysis 

Senores Pharmaceuticals Limited’s financial analysis reveals a mixed performance. Revenue has grown significantly, alongside increased equity, liabilities, PAT, EPS, RoNW, and total assets, highlighting the company’s strong financial growth and potential expansion. 

• Revenue Trend: The revenue increased from ₹141.70 millions in March 2022 to ₹353.37 millions in March 2023. The revenue for the current year’s 6-month period ending September 2024 is INR 1,810.18 million. 
• Equity and Liabilities: Both equities and liabilities have shown a consistent increase over the periods, reflecting potential growth and expansion. 
• Profitability: The profit after tax (PAT) has significantly increased from ₹9.91 million in March 2022 to ₹239.43 million by September 2024. This improvement in profitability could be a source of confidence among investors. 
• Earnings per Share (EPS): The diluted EPS has risen from ₹1.81 in March 2022 to ₹7.20 by September 2024, reflecting higher earnings per share for investors. 
• Return on Net Worth (RoNW): The RoNW has increased from 4.35% to 8.69%, indicating an increase in the company’s ability to generate returns on shareholder equity. 
• Financial Position: Total assets have increased, suggesting potential business growth. 

Senores Pharmaceuticals IPO Financial Analysis 

Senores Pharmaceuticals Limited IPO Peer Comparison 

Senores Pharmaceuticals Limited demonstrates growth among peers like Ajanta, Alembic, Caplin, Gland, and Strides. While peers showcase varying performance in margins and returns, Senores highlights robust potential, focusing on profitability and market positioning. 

Senores Pharmaceuticals Ltd IPO Objective 

The main objective of Senores Pharmaceuticals Limited is to invest in subsidiaries, fund sterile injection manufacturing, repay borrowings, and support working capital needs, ensuring financial stability and operational growth. 

1. Investment in one of their Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility: The company intends to utilise INR 107 crore for Havix’s expansion. The company will enhance injectable manufacturing capabilities at the Atlanta Facility to meet growing demand in regulated markets, focusing on high-value niche injectables and new dosage formats. 

2. Repayment/prepayment, in whole or in part, of certain borrowings availed by the company: The company plans to utilise INR 73.48 crore from the Net Proceeds to repay or prepay certain borrowings, improving its debt-equity ratio, enabling future growth and facilitating further investment in business expansion and development. 

3. Investment in their Subsidiary, namely, Havix, for repayment/prepayment in whole or in part of certain borrowings availed by Subsidiaries: The company aims to utilise INR 20.22 crore from the Net Proceeds to invest in Havix for repayment or prepayment of borrowings reducing indebtedness, improving the debt-equity ratio, and supporting future business growth and expansion. 

4. Funding the company’s working capital requirements: The company will utilise INR 43.26 crore from the Net Proceeds to fund its incremental working capital requirements for Financial Years 2025 and 2026, supporting its expansion and operational needs for critical care injectables and API manufacturing. 

5. Investment in their Subsidiaries, SPI and Ratnatris, to fund their working capital requirements: The company will utilise INR 28.82 crore and INR 30.66 crore from the Net Proceeds to fund the working capital requirements of its subsidiaries, SPI and Ratnatris, through equity investment and loan agreements, respectively. 

6. Funding inorganic growth through acquisition, other strategic initiatives, and general corporate purposes:  The company will deploy funds for general corporate purposes, including potential targets with R&D and manufacturing assets aligning with existing competencies and targets with synergies benefiting from management expertise, R&D, manufacturing, and distribution network. 

Senores Pharmaceuticals IPO Risks And Challenges 

Senores Pharmaceuticals Limited’s risk includes reliance on long-term marketing agreements, market growth in regulated and emerging markets, and strict quality standards. Failures could lead to product recalls, legal liabilities, customer loss, and financial setbacks. 

• The company faces risks from reliance on long-term marketing agreements with distributors in regulated and emerging markets, including competition, pricing pressures, and potential loss of key partners, which could impact business, financial condition, and operations. 

• The company’s revenue significantly depends on the growth of the Regulated Markets (US, Canada, UK) and Emerging Markets. A decrease in market growth or increased competition could adversely affect business, financial conditions, and cash flows. 

• Adherence to stringent quality standards is critical for the company. Failures may lead to product recalls, customer loss, legal liabilities, and audits with adverse observations. Non-compliance could negatively impact the company’s reputation, operations, and financial condition. 

Senores Pharmaceuticals Ltd IPO – Industry & Market Potential 

The global pharmaceutical sector is evolving, focusing on innovation, healthcare equity, and operational efficiency. Valued at USD 1,635.0 billion in 2023, the market is projected to reach USD 2,251.0 billion by 2028, growing at 6.6% CAGR. 

India’s API market, valued at USD 13.1 billion in 2023, is projected to grow at a CAGR of 14.2%, reaching USD 25.5 billion by 2028, driven by rising demand, government support, and shifting supply chain strategies. 

India’s pharmaceutical formulation exports grew from USD 13.9 billion in 2018 to USD 20.9 billion in 2023, with projections to reach USD 37.5 billion by 2028. API exports also rose from USD 3.8 billion to USD 4.7 billion. 

Senores Pharmaceuticals Limited IPO – Type of Offer 

Senores Pharmaceuticals Limited plans a fresh issue of 1.28 crore shares, seeking INR 500 crores to fund subsidiaries, repay borrowings, support working capital, and pursue strategic growth. Additionally, the company proposes an offer to sell 0.21 crore existing shares worth INR 82.11 crores. 

1. Fresh Issue: The company will issue 1.28 crore new shares to raise capital, aiming to collect INR 500 crores. The company intends to utilise the proceeds from the fresh issue to fund subsidiaries, repay borrowings, support working capital, and pursue strategic growth.
2. Offer for sale: Senores Pharmaceuticals Limited is offering to sell 0.21 existing shares worth INR 82.11 crores. The following are the details of the existing shareholders who are also the promoters selling the shares:

Senores Pharmaceuticals IPO Offer Size 

The offer size of Senores Pharmaceuticals Limited is INR 582.11 crores, consisting of a fresh issue of 1.28 crore shares worth INR 500 crores and an offer to sell 0.21 crore existing shares worth INR 82.11 crores. The company aims to fund subsidiaries, repay borrowings, support working capital, and pursue strategic growth. 

Senores Pharmaceuticals Limited IPO Allotment Structure 

Senores Pharmaceuticals Limited’s allocation will be as follows: 75% for Qualified Institutional Buyers (QIB), 15% for Non-Institutional Investors (NII), and 10% for Retail Individual Investors (RII) according to SEBI regulations. 

● Qualified Institutional Buyers (QIB): As per SEBI regulations, 75% of the shares offered through the IPO will be reserved for Qualified Institutional Buyers. These include entities such as banks, mutual funds, and insurance companies.

● Non-Institutional Investors (NII): 15% of the shares will be reserved for Non-Institutional Investors. These typically include corporate bodies or individuals investing more than Rs.2 lakhs.

● Retail Individual Investors (RII): The remaining 10% of the shares will be allotted to Retail Individual Investors. These individual investors apply for shares with a total value of less than Rs.2 lakhs. 

How to apply for Senores Pharmaceuticals IPO?

To apply for the Senores Pharmaceuticals Limited IPO through Alice Blue, follow these steps:

Open a Demat and Trading Account: If you don’t have one already, you must open a Demat and trading account with Alice Blue.

1. Check for IPO Details: Once your account is active, you can check for the Senores Pharmaceuticals Limited IPO details in the IPO section of the Alice Blue platform.
2. Place the Bid: Enter the number of shares you wish to buy and place your bid within the IPO’s price band.
3. Submit the Application: Confirm all your details and submit your application.

 You can apply for the Senores Pharmaceuticals Limited IPO at Alice Blue in just a few clicks!

Check Allotment Status: After the allotment process, you can check the allotment status to see if you have received any shares.

Please note that the allotment of shares is not guaranteed and will depend on the demand for the IPO.

How do you check Senores Pharmaceuticals IPO Allotment Status?

Checking the allotment status of an IPO in Alice Blue is usually straightforward. Please follow these general steps:

1. Log in to your Alice Blue Account: You can do this through the Alice Blue website or the trading app.
2. Navigate to the Portfolio or IPO Section: This might differ based on the layout of Alice Blue’s platform, but generally, you can find the status of your IPO application under the ‘Portfolio’ or ‘IPO’ section.
3. Find the IPO Allotment Status: Look for a sub-section called ‘IPO Allotment Status’ or something similar. This is where you can see the status of the IPOs you have applied for.
4. Select the Senores Pharmaceuticals Limited IPO: If you have applied for multiple IPOs, there might be a dropdown menu or a list where you can select the IPO you are interested in. Select the Senores Pharmaceuticals Limited IPO.
5. Check the Status: The status of your application should be displayed here. If the shares have been allocated to you, it would be mentioned here.

 If you face any issues, we request you reach out to our customer support team at Alice Blue for detailed assistance. 

 Apart from Alice Blue, there are other ways to check the allotment status of the Senores Pharmaceuticals Limited IPO:

● Registrar’s Website: Visit the website of Link Intime India Private Limited, the registrar of the Senores Pharmaceuticals Limited IPO. On the homepage, look for the ‘IPO Allotment Status’ option. You must enter your PAN, application, or Demat account number to check your allotment status. Click on the ‘Submit’ button to view your IPO allotment status. 

● BSE NSE: You can also check the allotment status on the official websites of the Bombay Stock Exchange (BSE) National Stock Exchange (NSE). You would need your application number and PAN to check the status. 

Please note that the allotment status will only be available after completing the allotment process, a few days after the IPO window closes.

Senores Pharmaceuticals Ltd IPO Offer Registrar

The registrar for the Senores Pharmaceuticals Limited IPO is Link Intime India Private Limited. They are responsible for ensuring the IPO allotment and refund processes are carried out smoothly.

Contact information for the registrar: 

Link Intime India Private Limited

C 101, 1st Floor, 247 Park

Lal Bahadur Shastri Marg, Vikhroli (West)

Maharashtra, India 400083

Tel: +91 8108114949

E-mail: [email protected]

Website: www.linkintime.co.in 

Senores Pharmaceuticals IPO – FAQs